1362MO Pembrolizumab + Olaparib Vs Abiraterone (abi) or Enzalutamide (enza) for Patients (pts) with Previously Treated Metastatic Castration-Resistant Prostate Cancer (mcrpc): Randomized Open-Label Phase III KEYLYNK-010 Study

E.Y. Yu, S.H. Park,J.C.H. Goh, S.J. Shin, N. Mehra,R. McDermott, M.A. Sala Gonzalez,P.C. Fong, R. Greil,M. Retz, J.P. Sade,Y-H. Huang,S. Begbie, F. Rey,G. Kramer, H. Suzuki, J. Zhang, J. Kim,C.H. Poehlein,E.S. Antonarakis

Annals of Oncology（2022）

Cited 0|Views0

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined